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Abstract
Human cells from acute myeloid leukemia (AML) patients are frequently transplanted into immune-compromised mouse
strains to provide an in vivo environment for studies on the biology of the disease. Since frequencies of leukemia re-
initiating cells are low and a unique cell surface phenotype that includes all tumor re-initiating activity remains unknown,
the underlying mechanisms leading to limitations in the xenotransplantation assay need to be understood and overcome to
obtain robust engraftment of AML-containing samples. We report here that in the NSG xenotransplantation assay, the large
majority of mononucleated cells from patients with AML fail to establish a reproducible myeloid engraftment despite high
donor chimerism. Instead, donor-derived cells mainly consist of polyclonal disease-unrelated expanded co-transplanted
human T lymphocytes that induce xenogeneic graft versus host disease and mask the engraftment of human AML in mice.
Engraftment of mainly myeloid cell types can be enforced by the prevention of T cell expansion through the depletion of
lymphocytes from the graft prior transplantation.
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Introduction
Xenotransplantation has become an indispensable tool for the
study of human stem cell biology in vivo, and the continuous
development of novel recipient mouse strains documents the high
interest and use of this technology [1–5]. Using mice as surrogate
organisms has the advantage that adult human stem cells, including
hematopoietic stem cells and cancer stem cells can be modulated
and effects analyzed in vivo. In fact, cancer stem cells are defined by
their capacity to re-initiate human tumors after transplantation into
mice [6], but variations in the transplantation settings and the use of
different recipient mouse strains resulted in inconsistent results on
the frequency and phenotype of this cell type [7–11] pointing at the
urge to determine the frequency of tumor re-initiating activity in
non-fractionated material in a robust xenotransplantation assay.
Furthermore, antibody coating of human cells might influence the
engraftment capability and bias the identification of stem cells
according to their surface markers [10].
Acute myeloid leukemia (AML) is a rare, heterogeneous
malignancy that originates from hematopoietic cells [12]. Treat-
ment therapy usually results in complete remission in the majority
of patients younger than 65. However, most patients will relapse
and only 30% of adults diagnosed with AML are expected to
survive three or more years [12]. Relapse of the disease may be
explained by the outgrowth of a small fraction of tumor cells that
survived therapy and that have the capacity to re-initiate the
tumor [13]. It has been suggested that these surviving tumor cells
represent the cancer stem cell fraction that re-initiates the tumor
growth in mice [13]. The concept that cancer stem cells contain all
tumor re-initiating activity is clinically of major importance
because of its potential impact on therapy [14–20]. However,
the cancer stem cell concept was recently challenged by
experiments that evidenced tumor re-initiating activity outside
the cancer stem cell fraction in AML material [7–10]. Further-
more, engraftment capacity of human cells can be negatively
affected by antibody coating [10]. Thus, to analyze tumor re-
initiation activity present in AML samples, it is necessary to
transplant non-fractionated, non-marked tumor cells, and to score
AML engraftment by analyzing donor-derived diseased cells.
Results
Factors Altering the Engraftment of Human AML in NSG
Mice
To optimize the transfer of non-separated AML cells from
human patients into mice, we aimed at determining the optimal
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transplantation settings. We compared the engraftment of freshly
isolated or stored MNCs from AML patients in non-conditioned
or irradiated NSG recipient mice (Figure 1). MNCs of 19 primary
AML samples were isolated from blood (PB, n= 6), bone marrow
(BM, n= 9) and leukapheresis products (LPH, n= 6) (Table 1) and
transplanted into NSG mice. BM chimerism larger than 0.1% was
considered as successful AML engraftment [11], and was observed
in almost all analyzed mice from all treatment groups (thawed
AML/non-conditioned recipients 95.7%, thawed AML/irradiated
recipients 100%, fresh AML/non-conditioned recipients 76.3%,
fresh AML/irradiated recipients 100%). Strikingly, only about half
of NSG recipient mice survived the scheduled time period after
transplantation (12–16 weeks). The parameters promoting pre-
mature death was irradiation conditioning of the recipient mice
and the use of fresh versus thawed donor-cells (Figure 1A). Thus,
survival of the recipient mice depends on the conditioning regimen
and the processing of the donor material.
To assess for potential influence of graft-processing and
transplantation procedure on the engraftment kinetics and
quantity we compared engraftment of donor-cells between the
four treatment groups. There were no changes concerning the
maximum donor-cell chimerism, reconstitution kinetics in the
blood of the recipient mice, and donor-cell chimerism in the bone
marrow at the time point of analysis (i.e. at the planned sacrifice or
the premature death of the animals)(data not shown). Source of
donor-cells influenced chimerism in the bone marrow of the
recipient mice in favor for leukapheresis (LPH)-derived donor cells
over bone marrow donor cells (Figure 1B). However, maximum
peripheral blood chimerism, reconstitution kinetic, overall survival
of the recipient mice, and the type of engraftment were again not
statistically different between the different graft sources (Figure
S1A-D).
We conclude that the extent and kinetic of the engraftment of
MNCs from human AML patients is independent of sample
processing or conditioning of the recipient mice. However, sample
processing and conditioning of the recipient mice are crucial
factors determining survival of the recipient mice.
Heterogeneity in Extent and Engrafted Cell types after
Transplantation of Mononucleated Cells from AML
Patients
To analyze the reproducibility and the quality of engraftment
we transplanted the same number of MNCs from AML patients
into several NSG recipient mice and analyzed the frequency of
human leukocytes. Results of a representative AML (AML #9,
Table 1) transplantation is shown in Figure 2A. We found large
differences in the magnitude of engraftment between recipients of
the same donor-cells (20%, 39%, and 85%). Furthermore, analysis
of the cell surface expression of CD3, CD19, and CD33 on human
leukocytes in the bone marrow of recipient mice also revealed a
striking difference between recipients of the same donor-cells that
ranged from very low (,1%, Figure 2A, top) to very high (82%
middle) frequencies of myeloid cells (CD33+). Consistently, CD3+
T cells and CD19+ B cells were also found to different frequencies.
Consequently, we observed a very high variability in the
engraftment of different AML samples (Figure 2B). (I) Mainly
CD3+ cells, (II) multilineage engraftment including CD3+, CD19+
and CD33+ cells, and (III) robust engraftment of CD33+ cells.
However, in the bone marrow, blood and spleen of most of the
recipient mice, we mainly detected CD3+ cells (Figure 2C). B-
Figure 1. Sublethal irradiation and fresh donor cells reduces survival in NSG mice transplanted with AML-MNCs. (A) Kaplan-Meyer
plot of mice that were transplanted with MNCs of AML patients. NSG mice were transplanted with freshly isolated MNCs with (fresh/irradiated; grey
solid line) and without (fresh/non-conditioned; black solid line) previous conditioning, or thawed MNCs with (thawed/irradiated; grey dotted line) or
without (thawed/non-conditioned; black dotted line) sublethal irradiation. The percentage of mice transplanted and available for bone marrow
analysis is indicated below graph (BM analysis available). Using fresh donor cells and irradiation conditioning shortened the life span of the recipient
mice (fresh/irradiated vs fresh/non-conditioned p=0.007; thawed/irradiated vs thawed/non-conditioned p= 0.018; and fresh/irradiated vs thawed/
irradiated p= 0.0054; fresh/non-conditioned vs thawed/non-conditioned p= 0.0051; Gehan-Breslow-Wicoxon Test). Rx = irradiation conditioning. (B)
Plot shows the bone marrow chimerism (percentage of human CD45+ cells of total CD45+ cells) after the transplantation of AML samples from bone
marrow (BM), peripheral blood (PB), and leukapheresis products (LPH) 12–16 weeks before. LPH-MNCs showed a significant increase in the bone
marrow overall chimerism compared to BM-MNCs.
doi:10.1371/journal.pone.0060680.g001
Xenogenic AML Transplantation
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e60680
lymphocytes (CD19+) and myeloid cells (CD33+), which may
include potential AML blasts represented a minority of human
leukocytes in all analyzed organs. To test whether the cellular
composition of the graft determines the type of engraftment, we
analyzed in a large cohort of recipient mice whether the frequency
of T cells, AML blasts in the graft, or total leukocytes in the
patients correlated with dominant T cell or myeloid cell
engraftment in the recipient mice. None of the tested graft
parameters correlated significantly with the type of engraftment in
the recipient mice (Figure S2), suggesting that a stochastic
mechanism determines the type of engraftment. Taken together,
engraftment of AML samples in NSG mice shows a large
heterogeneity with respect to the extent and quality of the
engraftment.
In conclusion, using 19 AML samples we showed that the extent
of engraftment and the cellular composition of the engrafted
human leukocytes are independent from the cellular composition
of the graft, and that irrespective of the patient sample used,
mainly human CD3+ cells are found in blood, bone marrow and
spleen of recipient mice.
CD3+ Cells are Donor-derived Polyclonal T Lymphocytes
To determine the identity of hCD45+CD3+ cells we performed
a morphological analysis (Figure 3A), and found typical lymphoid
cells (small cells, large nucleus, few cytoplasm, dark blue stained
cytoplasm) as well as cells with a different morphology (large cells
with large nuclei, more cytoplasm and lightly blue stained
cytoplasm), suggesting that hCD45+CD3+ cells contain morpho-
logically distinct populations, potentially including activated T
lymphocytes. CD3 was not aberrantly expressed on AML blasts in
the transplanted material (not shown), suggesting that
hCD45+CD3+ cells are not diseased cells but rather expanded,
graft-derived co-transplanted T cells. Consistent with this inter-
pretation, CD3+ donor cells could be separated into subpopula-
tions expressing either the alpha/beta T cell receptor (TCRa/b)
or the gamma/delta TCR (TCRc/d). Furthermore, TCRa/b+
cells were a heterogeneous population that included CD4 or CD8
single positive or CD4 CD8 double positive cells (Figure 3B),
confirming the presence of distinct T lymphocyte populations in
the recipient mice.
Next, we asked whether human T cells in NSG recipient mice
were of mono- or oligoclonal origin. Most T cell malignancies are
characterized by a monoclonal expansion of T lymphocytes [26],
whereas the simultaneous activation of T cells that occurs for
example in the context of graft versus host disease (GvHD) usually
represents an at least oligoclonal event [27]. To discriminate
between T cell neoplasm and non-malignant causes for the
increase of T cell numbers after transplantation, we analyzed the
Table 1. Characteristics of samples from 19 AML patients.
blast-
gate CD3+ CD34+
CD34+
CD38- fresh thawed
no. FAB genetics
molecular
aberration
clinical
cstatus source
leuco
(Gpt/l) gender
age
(years)
% of
hCD45+
% of
blast-gate no-Rx Rx no-Rx Rx
1 4 int. NPM1 initial PB 64.4 F 66 64.2 2.29 10.7 0 X
2 2 int. refractory BM 4.5 F 59 39.6 26.8 7.99 0.158 X
3 6 int. initial BM 2.01 M 74 49.7 6.97 4.16 0.0258 X
4 1 int. NPM1 initial BM 3.17 F 69 94.1 4.03 0.136 0.0317 X X
5 5 high initial BM 9.24 M 22 85.4 8.93 93.9 0.405 X
6 5 int. NPM1,
FLT3-ITD
initial LPH 46.85 M 59 83.8 6.57 0.266 0.0133 X X
7 1 int. NPM1 initial LPH 240.24 F 67 88.8 6.08 0.763 0 X X X
8 1 int. NPM1 initial PB 155 F 42 95.6 1.81 0.19 0 X
9 1 int. NPM1 initial PB 104.88 F 52 94.3 2.19 7.79 0.136 X X X
initial BM 94.2 2.35 7.27 0.091
10 6 int. initial BM 10.48 M 53 13.5 16.9 2.35 0.0417 X X X X
11 1 int. NPM1,
FLT3-ITD,
FLT3-TKD
initial LPH 135.19 F 70 90.1 2 44.4 0.0942 X X
relapse PB 59.3 F 70 92.7 2.66 36.8 2.22 X
12 2 int. initial PB 44.08 M 72 93 0.293 82.4 0 X X
13 5 int. NPM1,
FLT3-ITD
initial LPH 337.31 F 49 93.9 4.76 3.29 0.0234 X
14 2 int. refractory BM 2.9 M 76 69.2 7.34 22.3 0.0343 X X
15 n.a. int. relapse PB 36.69 M 69 91.4 1.48 61.9 0.486 X X
16 1 high initial BM 3.81 F 70 76.7 7.86 36 0.0236 X
17 5 int. NPM1 relapse LPH 203.64 M 61 93.2 2.27 0.044 0.00161 X X
18 0 int. initial LPH 132.11 M 73 94.5 1.89 71.5 0,8181 X X
19 2 high relapse BM 1.61 F 51 28 45.2 93.7 19.6 X X
BM=bone marrow, F = female, FAB = French-American-British-classification, FLT3-ITD= Internal tandem duplication of FLT3, FLT3-TKD= Tyrosine kinase domain
mutation of FLT3, Int. = intermediate, LPH = leukapheresis, M =male, n.a. = not available, NPM1= nucleophosmin1 mutated, PB = peripheral blood, Rx = irradiation.
doi:10.1371/journal.pone.0060680.t001
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use of variable segments of the TCR beta chain (Vb) on CD3+ T
cells in the blood of healthy individuals and NSG mice that were
transplanted with MNCs from AML patients (Figure 3C). In man,
TCR Vb chain usage was very uniform between individuals, and
the mean prevalence of the TCR Vb chain in mice was similar to
the distribution observed in healthy donors, suggesting that an at
least oligoclonal expansion of co-transplanted T cells is the basis
for the over-representation of CD3+ T cells in the human graft.
We conclude that engrafted hCD45+CD3+ cells are polyclonal
T cells that show the same relative distribution of Vb chain usage
compared to man, suggesting that mature co-transplanted T cells
expanded in the recipient mice.
Donor-derived Co-transplanted T Cells Induce
Xenogeneic Graft Versus Host Disease
To determine whether the symptoms of prematurely diseased
mice depended on diseased myeloid cells or expanded T
lymphocytes, we analyzed leukocyte engraftment in unconditioned
mice that had received MNCs from healthy donors (Figure S3).
Irrespective of the graft source (PB or BM or PBMC), 82% of
recipients of MNCs from healthy patients developed the same
symptoms, as did mice that were transplanted with MNCs from
AML patients, and showed a reduced survival accompanied by
pale bones harboring reduced numbers of cells, and enlarged
spleens (Figure S3 and S4). However, NSG mice that had received
MNCs from healthy donors showed differences in the overall
human chimerism (hCD45+) in the analyzed organs (Figure S4B),
but virtually all engrafted human leukocytes where CD3+ T
lymphocytes (.93% in PB, BM and spleen, Figure S4C). Further,
the majority of mice that deceased prematurely tended to have a
lower myeloid chimerism (27.9%623.9% vs. 40.0%624.3%) and
a higher T cell chimerism (58.6%623.7% vs. 1.5%63.0%)
compared to mice that survived until the scheduled end of the
experiment without signs of illness. Therefore, an elevated T cell
chimerism seems to be predictive for premature death, and these
findings support the interpretation that disease symptoms are
induced by expanded co-transplanted donor-derived T lympho-
cytes.
Human T lymphocytes in NSG mice that received MNCs from
healthy donors showed a similar expression of the co-receptors and
diversity in the TCR Vb segment use compared to T cells in NSG
recipients of AML-MNCs (Figure S4D and E), suggesting that
after the transplantation of MNCs from healthy individuals into
NSG recipient mice polyclonal human T lymphocytes expanded.
The symptoms of prematurely deceased mice are similar to
those suffering from xGvHD [28–34]. Because the activation
status of donor T lymphocytes directed against host antigens is a
central part of the pathophysiology of GvHD [35] and xGvHD
[36], we further analyzed for surface activation-markers CD25
and CD69 in the blood, BM and spleen of recipient mice
(Figure 3D,E) [35,36]. In the blood only a small fraction of
hCD45+CD3+ cells expressed activation markers, whereas, in the
bone marrow and spleen large fractions of donor-derived T cells
were activated after the transplantation of MNCs from AML or
healthy donor-derived cells (Figure 3D and Figure S4F). Organ-
specific imbalance in the frequency of activated T cells was
observed to a much lower extent in healthy donors (Figure 3E),
suggesting that T cells from both donor groups were activated after
transfer, and that the pathophysiology of xGvHD in all NSG
recipient mice had the same cause.
Bone marrow hypoplasia, a dominant sign of xGvHD [31],
occurred more pronounced in NSG recipient mice that had
received MNCs from healthy donors compared to AML donors
(Figure S3). To assess whether this effect was mediated by different
T cell doses that were co-transplanted with MNCs from AML
patients (7.568.46105, n= 14) or healthy donors
(27.4623.56105, n = 9), we transplanted titrated numbers of
sorter-purified human CD2+ T cells into NSG recipient mice and
analyzed human T lymphocyte frequencies in the blood (Figure 3F)
and bone marrow (Figure 3G) of the recipient mice. Human T cell
engraftment ($0.1% CD3+ T cells within the fraction of human
leukocytes) was exclusively detected in mice that were transplanted
with $105 T cells. Maximum chimerism of the peripheral blood
and BM chimerism correlated with the number of transplanted
CD2+ cells (Figure 3F and E). However, other factors seem to
influence T cell engraftment since there was a lack of correlation
between the number of engrafted T cells and co-transplanted T
lymphocytes after the transfer of MNCs from AML patients
(Figure S2A).
We conclude that co-transplanted donor T lymphocytes
expanded in NSG recipient mice, became activated and mediated
xGvHD that occurred independent from AML disease in the
donor.
Engrafted T Lymphocytes are not of Acute Myeloid
Leukemia Origin
Malignant transformation of hematopoietic precursors is
considered as the underlying cause of leukemogenesis [37–40].
To discriminate between regular and disease-related hematopoi-
esis and to determine whether mutant Npm1, a founder genetic
lesion in AML, ultimately leads to the proliferation of diseased cells
of the myeloid and lymphoid lineages [41,42], we transplanted
MNCs from three patients that carried mutant Npm1 into mice
and monitored for the molecular aberration in cells of the myeloid
and lymphoid lineages at the time point of analysis.
Three AML samples with Npm1 mutations (#7–9, Table 1),
which had shown mixed engraftment in previous experiments, and
from which sufficient primary material was still available were
chosen to elucidate the origin of engrafted human myeloid and
lymphoid cell types (CD33+, CD3+ and CD19+). AML-MNCs
were transplanted in sublethally irradiated mice. Molecular
analysis from sorted donor-derived cells from the bone marrow
of recipient mice revealed that only donor-derived myeloid cells,
but not T or B lymphocytes carried mutant Npm1 alleles,
suggesting a distinct cellular origin of cells of the myeloid and
lymphoid lineages at the time point of differentiation (Table 2).
These results confirm the independence of T cell expansion from
AML diseased cells, and suggest that the putative AML-initiating
Figure 2. Intra- and inter-sample heterogeneity in the engraftment of MNCs from AML patients. (A) Dot plots show the frequency of
human leukocytes in the bone marrow of three NSG recipient mice that were transplanted with MNCs from the blood from AML patient#9 (Table 1),
7–10 weeks before (left column). Human cells were further analyzed for the cell surface expression of CD3 versus CD33, and CD33 versus CD19
(middle and right column, respectively). (B) Dot plots show human leukocytes in the bone marrow of NSG recipient mice that were transplanted with
MNCs from LPH, BM or PB from AML patients #18, #14, and #12 (Table 1), respectively. Human leukocytes were analyzed for the expression of CD3,
CD19 and CD33 six weeks (AML #18 and #14) or ten weeks (AML #12) after transplantation. (C) Frequency of CD3, CD19 or CD33 positive human
leukocytes in the blood (PB, asterix), bone marrow (BM, circles) and spleen (diamonds) of NSG mice are presented as percentage of human CD45+
cells. The number of AML-samples (AML), independent experiments (exp.), and recipient mice (mice) is indicated.
doi:10.1371/journal.pone.0060680.g002
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Figure 3. Human CD3+ cells in NSG recipient mice are polyclonal activated T lymphocytes. (A) Human CD3+ cells are morphologically
diverse. Sorted human CD45+CD3+ cells (sort purity: 98.6%) isolated from the bone marrow of a NSG recipient mouse that had received 56106–107
freshly isolated MNCs from AML #10 three weeks before were cytospun and stained according to May-Gru¨nwald Giemsa. (Graft phenotype in the
recipient: bone marrow: 35% hCD45+; composition of human leukocytes: CD3+= 93%, CD19+= 0.8%, CD33+=0.8%; surface antigens on CD3+ cells:
Xenogenic AML Transplantation
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driver mutation occurred within a cell that could not give rise to
lymphocytes any more, thus the cells of origin of these leukemias
were not multipotent, but myeloid-restricted hematopoietic
precursor cells [41].
Depleting CD3+ T Cells from the Graft Strengthens AML
Engraftment
We showed that engraftment of diseased myeloid cells can occur
independently from the engraftment of lymphoid cells in NSG
mice (Table 2). To determine whether xGvHD can be circum-
vented and whether we can augment the engraftment of AML-
diseased cells, we transplanted MNCs from AML patients #7–9
that where sorter-depleted for T and B lymphocytes (sort purity
.99.5%) in sublethally irradiated recipients, and analyzed
lymphoid and myeloid engraftment in the recipient mice 12
weeks later (Figure 4). AML blasts of patient #7–9 shared a
common, characteristic phenotype of Npm1-mutated AML:
CD33+CD342CD117+. This phenotype was distinguishable from
the surface profile of MNCs from a healthy individual, and was
therefore used as a marker to follow diseased AML cells after
transplantation (Figure 4A). At the time point of analysis, co-
transplanted T lymphocytes had expanded and constituted a large
proportion of the graft, whereas no T cells were detected in the
bone marrow of recipient mice that had received lymphocyte-
depleted MNCs from AML #7–9. Moreover, in recipients of
CD32CD192 MNCs .90% of all engrafted human leukocytes
were of the myeloid lineage (CD33+) and the majority of engrafted
human myeloid cells showed the same phenotype compared to
diseased AML #7–9 before transplantation, suggesting that
predominantly diseased AML cells engrafted and expanded.
Consistent with this interpretation a very high percentage of
human leukocytes localized in the ‘blast gate’ (SSC versus CD45),
that is clinically used for the identification of diseased leukemic
cells, in recipient mice of lymphocyte-depleted MNCs but not in
recipients of MNCs. There were no differences in bone marrow
chimerism (Figure 4B) or the percentage of CD19+ cells in the
recipient mice (Figure 4C). In contrast, CD3+ cells significantly
decreased after the transfer of lymphocyte-depleted MNCs in all
experiments (Figure 4D), preventing the development of xGvHD.
Consequently, none of the mice receiving CD32CD192 MNCs
showed deterioration of health, while two mice transplanted with
non-fractionated AML-MNCs had to be sacrificed ahead the
scheduled end of the experiment (5.8 and 6.4 weeks after
transplantation, respectively). Furthermore, the engraftment of
CD33+ cells was significantly increased after the transplantation of
lymphocyte-depleted MNCs compared to non-depleted MNCs
(Figure 4E), suggesting that the engraftment of diseased myeloid
cell types was augmented in all experiments. Again, mice
transplanted with non-fractionated AML-MNCs tended to have
a larger spleen compared to mice transplanted with CD3/CD19-
depleted MNCs (murine and human leukocytes (CD45+):
0.6861.096106 cells vs. 0.2260.176106 cells; not statistically
significant). The bone marrow cellularity of mice transplanted with
CD3/CD19-depleted cells was non-significantly reduced com-
pared to control animals (murine and human leukocytes (CD45+):
1.3560.346106 cells vs. 1.6560.176106 cells), whereas mice
receiving non-fractionated AML-MNCs showed a significant
reduction in cellularity (1.260.24 x106 cells).
In conclusion, depleting T cells from AML grafts, prevents the
expansion of T cells and the occurrence of xGvHD in the recipient
mice and leads to a uniform engraftment of diseased CD33+
myeloid cells.
Discussion
A robust assay to test for human leukemia re-initiating cells
in vivo is lacking. Despite the differences between mice and men
the use of mice as recipients for leukemia samples will allow the
analysis of human tumor biology in an in vivo microenvironment.
In contrast to previous publications [43–45], we show here using
NSG recipient mice, that a robust engraftment of human myeloid
cell types is a rare event upon the transplantation of MNCs from
AML patients and that the same donor sample can show different
patterns of engraftment in distinct recipient mice. We show that
co-transplanted, polyclonal T lymphocytes expand and we further
define a threshold for the transfer of donor T cells that is
compatible with the transplantation of AML cells. Last, we show
CD4+=80%, CD8+= 14%, CD4+/CD8+= 3%, TCRa/b+= 99%, TCRc/d+= 0.02%). Photograph is representative for 6 different AML samples. Scale bar
indicates a section of 10 micrometers. (B) Human CD3+ cells are identified as T lymphocytes by the surface expression of the T cell receptors (TCRs)
and co-receptors. Graph shows a summary of the expression of TCRa/b or TCRc/d, and the expression of CD4 and CD8 on CD3+ cells the bone
marrow of NSG mice that were transplanted with AML-MNCs as described in (A) (Within CD3+ cells: TCRc/d: 5.0615.2%, TCRa/b: 89.2622.1%; Within
TCRa/b+ cells: CD4+ CD82: 66.2623.6%, CD42 CD8+: 20.2619.2%, CD4+ CD8+: 9.3614.5%.) (C) Plot shows the frequency of indicated Vb segments
used in human a/b T cell receptors on T cells in the blood of healthy controls (‘in man’) and in the bone marrow of NSG mice that had received MNCs
from AML patients as described in (A, ‘in mice’). Frequencies based on human CD45+ CD3+ cells are shown. (D) Bar graph shows the frequency of
human T lymphocytes (hCD45+CD3+) that express CD25 and CD69 in blood, bone marrow and spleen of NSG mice that were transplanted with 107
MNCs from AML patients 9.762.2 weeks before. N= 53 for all groups. (E) Bar graph shows the frequency of T lymphocytes that express CD25 and
CD69 in the peripheral blood (4.760.3% of T lymphocytes) and bone marrow (21.9610.2%) of healthy donors. N = 3 for all groups. (F) Maximum
blood chimerism was determined after the transplantation of titrated numbers of CD2+ T cells that were sorted from the peripheral blood of a healthy
donor. Donor-cell chimerism $0.1% hCD45+ (considered T cell engraftment, left y-axis) was reached only if $105 CD2+ cells were transplanted.
Virtually all engrafted human leukocytes expressed CD3 (% hCD45+CD3+, right y-axis). Mean and standard deviation are shown. (G) Plot depicts
donor-cell chimerism in the bone marrow of NSG recipient mice as described in (D). Mean and standard deviation are shown.
doi:10.1371/journal.pone.0060680.g003
Table 2. Mutational analysis of Npm1 in engrafted human
leucocytes.
CD3+ T cells CD19+ B cells
CD33+ myeloid
cells
AML #7 Wild type Wild type mutant
Wild type Wild type mutant
AML #8 Wild type Wild type mutant
Wild type Wild type mutant
Not available Wild type Not available
AML #9 Wild type Wild type mutant
Wild type Wild type mutant
Thawed MNCs of Npm1-mutated AMLs #7–9 were transplanted into irradiated
NSG recipients. Engrafted CD19+ B- and CD3+ T lymphoid and CD3- CD19-
CD33+ myeloid cells were sorted (sort purity .99% for each fraction) and
analyzed for presence of mutant Npm1. T- and B-lymphocytes in the bone
marrow of the recipients displayed wild-type Npm1, while myeloid cells were
positive for mutated Npm1.
doi:10.1371/journal.pone.0060680.t002
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that engraftment of myeloid cells can be obtained through the
depletion of T lymphocytes from the graft, thereby transferring all
other cells that may have the potential to re-initiate a human
tumor in mice.
It has become evident over the last few years that a common cell
surface phenotype identifying cancer stem cells in AML is missing
[7–11], suggesting that either the cancer stem cell theory is not
applicable or that the correct phenotype still awaits identification.
Furthermore, coating of human cells with antibodies might also
influence the engraftment capacity of stem cells [10]. In
conclusion, lack of a common cell surface phenotype for cancer
stem cells also means that the transplantation of titrated numbers
of bulk tumor cells into mice is necessary to obtain information on
the frequency of leukemia initiating activity in AML samples.
Further, recent data suggest that the use of suboptimal recipient
mice lead to an underestimation of cancer stem cell frequencies,
emphasizing the necessity to re-assess the presence, function and
frequency of this activity in AML samples [7–11]. Therefore we
aimed at re-addressing engraftment of human cells after the
transplantation of MNCs from AML patients into NSG recipient
mice. We frequently detected engrafted human cells in the bone
marrow, blood and spleen of recipient mice as reported by other
laboratories [43–49]. However, in contrast to previous reports
[45,46,49], the capacity of human cells to engraft in mice failed to
correlate with the graft source, AML subtype, transplantation
procedure, or sample processing. Using MNCs as donor material
we found a striking variability in terms of engrafted donor-derived
cell types (T or B lymphocytes or myeloid cells) in recipient mice.
Irrespective of the cause for heterogeneity of engrafted cells, this
finding suggests that MNCs from AML patients are inappropriate
graft cells for the study of cancer stem cell frequency and biology.
For the study of a human myeloid cell type-based disease in
mice, human myeloid cells need to engraft. However, in contrast
to previous studies [43–45], we report here that the transplanta-
tion of MNCs from AML patients into NSG mice led to a
predominant engraftment of human T cells. Myeloid cells,
including putative diseased cells, only represented a minority of
engrafted human leukocytes. It has been suggested that tumor re-
initiating activity of AML samples resides in monoclonal T
lymphocytic leukemia re-initiating stem cells that expand in NSG
recipient mice [50]. However, we showed that the donor-derived
T cells were at least polyclonal and lacked expression of the
molecular marker of the transplanted AML cells. Others reported
on the appearance of only a minor population of T cells in a small
fraction of recipient mice after the transplantation of MNCs from
AML patients [45]. This work was restricted to AML samples with
.80% blasts, which might contribute to the differences in
lymphoid and myeloid engraftment compared to our results.
However, in our cohort even samples with .80% blasts showed
expansion of human CD3+ cells. Further studies focused on the
detection of human leukocytes (hCD45+ [43,46]) or myeloid but
not lymphoid cells of human origin [44] as a measure for human
donor cell engraftment. Thus, the frequency of lymphoid donor-
derived cells in those studies is not known.
Taken together, we show here that the transplantation of MNCs
from AML patients frequently results in the polyclonal expansion
of co-transplanted T lymphocytes but not in engraftment of cells of
the myeloid lineage.
Expansion of human T cells in mice has been reported in studies
focusing on the establishment of xGvHD models by transplanting
MNCs of healthy donors [28–31,34,36,51,52]. Comparing two
mouse strains, Ali and coworkers were able to demonstrate that
NSG mice are especially susceptible to xGvHD [51]. Interestingly,
the incidence of xGvHD seems to be associated with the HLA
class-I alleles expressed by the human donor [52]. Similar to our
data, the predominant expansion of human T cells prevented the
engraftment of non-malignant hematopoietic stem cells [32].
Nevertheless, predominant T cell engraftment after transplanta-
tion of MNCs from patients with malignant myeloid diseases was
apparently also observed by others, as T cell depletion is described
in the ‘material and method’ section of some studies [53–56].
Furthermore, lethal xGvHD was also observed when transplanting
human MNCs to achieve engraftment of chronic lymphocytic
leukemia (CLL) suggesting a similar phenomenon for lymphoid
diseases [57]. Nevertheless, T cell expansion after transplantation
of AML-MNCs or MNCs from patients with low-risk myelodys-
plastic syndrome (MDS) has only been incompletely described so
far [54–56]. Consistent with our data the foremost phenotype of
xGvHD in NSG mice is bone marrow hypoplasia accompanied by
peripheral cytopenia most likely causing death [31,51,52]. We
showed that donor-derived T lymphocytes from healthy donors
and from AML patients acquire an activated phenotype in mice,
suggesting that xenoreactivity may cause expansion by activation.
Such a memory-type T lymphocyte phenotype is found in models
of xGvHD [51]. Even though higher numbers of transplanted T
cells were reported to aggravate xGvHD [31] there was no
evidence for a correlation between T cell chimerism and
transplanted donor T cell numbers, which may be explained by
a generally lower number of T cells that were co-transplanted with
the MNCs from AML patients, compared to the previously
reported minimum dose of T cell inoculum necessary for
engraftment [31]. Nevertheless, and in agreement with King et al.
we also observed a significant shortened median survival time of
sublethally irradiated recipients of AML-MNCs [31], supporting
the conclusion that xenoreactive donor-derived T cells expanded
polyclonally and led to death of the recipient mice.
In conclusion, we showed that the transfer of MNCs from AML
patients is not suitable for the analysis of frequency and biology of
tumor re-initiation activity in mice. Relative to previous attempts
to improve the engraftment of diseased human cells of the myeloid
lineage [54], we detected a significant increase in engrafted
diseased myeloid cells, suggesting that the transplantation of T cell
Figure 4. Depletion of CD3+ and CD19+ cells from the graft prevents xGvHD symptoms, and augments AML engraftment.
Unconditioned NSG mice were transplanted with equal numbers (0.15–0.66107 cells) of thawed MNCs from AML #7–9 (Table 1) with or without
previous depletion of CD3+ and CD19+ lymphocytes (CD32CD192MNC and MNC, respectively). Mice were sacrificed for bone marrow analysis 12
weeks after transplantation, or when detoriation of health occurred, and analyzed by flow cytometry. AML samples #7–9 showed a common,
characteristic phenotype of Npm1-mutated AML with positivity for CD33 and CD117, but lack of CD34 expression. (A) Dot plots show expression of
CD3 versus CD33 (left column), CD34 versus CD117 (middle), and side scatter (SSC) versus CD45 (right column) on human CD45+ MNCs from a healthy
donor (top), from AML patient#7 (second row from top), and from the bone marrow of NSG recipient mice that were transplanted with either MNCs
(second row from bottom) or CD32CD192MNCs (bottom) from AML #7 twelve weeks before. Data representative for all AML samples #7–9
analyzed. (B-E) Plots show the mean donor-cell chimerism (B, % hCD45+; MNC: 33.3627%, CD32CD192MNC: 22.4630.9%), the frequency of CD19+
cells (C, MNC: 18.5626.0%, CD32CD192MNCs: 12.3614.3%), or CD3+ cells (D, MNC: 42.4643.5%, CD32CD192MNCs: 0.0260.02%, p= 0.0247), or
CD33+ cells (E, MNC: 35.9636.3%, CD32CD192MNCs: 85.0617.8%, p = 0.0087) within donor-derived leukocytes (hCD45+) in the bone marrow of
recipient mice 6–12 weeks after transplantation with AML-samples #7–9 (MNC: 33.3627%, CD32CD192MNC: 22.4630.9%).
doi:10.1371/journal.pone.0060680.g004
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depleted MNCs from AML patients into NSG mice may represent
a robust model to re-assess presence, frequency and function of
leukemia stem cells.
Materials and Methods
Human Samples: Ethics Statement
Samples from healthy volunteers and AML patients were
obtained from patients at the University Hospital Dresden with
written informed consent according to protocols approved by the
Institutional Review Board (IRB), the Ethikkommission an der TU
Dresden. MNCs of peripheral blood (PB) and bone marrow (BM)
were isolated by density centrifugation on a Ficoll gradient.
Residual red blood cells of peripheral blood mononuclear cells
(PBMC) and leukapheresis products (LPH) were lysed (ACK
buffer, Invitrogen). Nucleophosmin (Npm1) and FMS-like tyrosine
kinase 3 (Flt3) mutation analysis was performed as described before
[21,22].
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD/SCID/IL2rc2/2,
NSG) mice were purchased from The Jackson Laboratory (Jackson
Laboratory, Bar Harbor, Maine, USA). NSG mice are character-
ized by the absence of mature T-, B- and NK-cells and show
additional defects in innate immunity [3,4]. Mice were kept under
specific pathogen-free (SPF) conditions in sterilized microventi-
lated cages with sterilized food and water ad libidum in the animal
facility at the Medical Theoretical Center of the University of
Technology Dresden. Experiments were performed in accordance
with German animal welfare legislation, and were approved by the
relevant authorities, the Landesdirektion Dresden (24-9168.11-1/
2009-33). Cell suspensions were prepared as described previously
[23]. Briefly, spleen and thymus were disintegrated by gentle
disruption between glass slides, while femuras and tibias were
crushed using a mortar. Red blood cells from spleen and bone
marrow samples were removed by lysis. May-Gru¨nwald Giemsa
staining was performed as described before [23].
Flow Cytometry
Samples were prepared as described before [23] using the
following antibodies recognizing human antigens (clones given in
brackets): CD45 (HI30, BioLegend), CD2 (RPA-2.10), CD19
(HIB19), CD34 (581), CD45 (HI30), TCRab (T10B9.1A-31, all
BD Biosciences), CD3 (UCHT1), CD3 (SK7), CD4 (SK3), CD8a
(RPA-T8 eB), CD25 (BC96), CD33 (HIM3-4), CD38 (HIT2),
TCRcd (B1.1 eB), TCR Vb 5.1 (LC4), TCR Vb 5.3 (3D11), TCR
Vb 8 (JR-2), TCR Vb 9 (AMKB1-2), TCR Vb 13.1 (H131), TCR
Vb 13.2 (H132) and TCR Vb 23 (AF23), anti-mouse CD45 (30-
F11, all eBioscience). FITC conjugated streptavidin was purchased
from BD Biosciences. Doublet discrimination was routinely
carried out and dead cells were excluded by 4, 6 diamidino-2-
phenylindole (DAPI)-staining. Analysis or sorting was performed
on BD LSRII or AriaII machines, respectively (BD Biosciences).
Purity of the CD32CD192 population was 100% (AML #7),
99.6% (AML #8) and 100% (AML #9). For T cell limiting
dilution transplantations, indicated numbers of CD2+ T lympho-
cytes (98.2% purity) from PBMC of healthy donors were
transplanted. Cells for molecular analysis of Npm1 were sorted to
98%62% (CD3+, n = 6), 98.8%60.8% (CD19+, n = 7), and
92%69% (CD33+, n = 7) purity. At least 300 cells were used for
mutation analysis of Npm1 as described before [24].
Transplantation
The age of mice used for experiments ranged between 3 to 6
weeks. Cell suspensions containing 56106–107 MNCs in 200 ml
PBS/5% FCS were injected intravenously as described before
[23]. 0.15–0.66107 CD32CD192 AML-MNCs were transplanted
in indicated experiments. For the first 3 weeks after transplanta-
tion, water was supplemented with neomycin (1.17g/l, Sigma). In
three experimental series mice were transplanted without prior
conditioning. To analyze factors that potentially influence
engraftment, we compared the engraftment kinetics and the
phenotype of human cells in non-conditioned and irradiated
recipient mice after transplantation of AML-MNCs (Figure 1A).
Furthermore, cells from healthy donors were exclusively trans-
planted in unconditioned mice to avoid excess of xenogeic Graft
versus Host Disease (GvHD) induced death (1. influence of the
transplanted T cell dose on the occurrence of xenogeneic GvHD,
Figure 3 F-G; 2. engraftment kinetics and phenotype of human
cells after transplantation of MNCs of healthy donors, Figure S4
A-F). In all other experiments mice received 100cGy whole body
irradiation (WBI), using an Yxlon MaxiShot X-ray irradiator
(Yxlon), between 4 to 24 hours prior to human cell injection.
Sublethal irradiation was chosen to enhance engraftment without
the necessity of complete hematopoietic replacement [25]. As
malignant cells have lost the ability to differentiate and to replenish
all kind of fully differentiated functional blood cells, lethal
irradiation would obligatory lead to death due to bone marrow
insufficiency, irrespective of the engraftment of human AML.
Mice were sacrificed 12–16 weeks after transplantation or earlier
when detoriation of health occurred (decreased activity, poor
grooming, weight loss, fur ruffling). All animal experiments were
approved by the local relevant authorities (‘Landesdirektion
Dresden’, Germany).
Supporting Information
Figure S1 Source of AML-MNCs influences the engraftment
kinetics of human leukocytes. MNCs from patients with AML
were isolated from bone marrow (BM), peripheral blood (PB) or
leukapheresis products (LPH), and 56106–107 MNCs were
transplanted freshly or after DMSO-based storage into non-
conditioned or irradiated NSG mice. Recipient mice were
sacrificed 12–16 weeks after transplantation or earlier when
detoriation of health occurred. (A) The maximum human
leukocyte chimerism in the blood during the observation period
is presented in dependency of the graft source. (B) The graph
shows the time point of the maximum peripheral blood chimerism
in mice that received MNCs from bone marrow, blood or LPH
samples from AML patients with AML. (C) Survival of mice
transplanted with MNCs from bone marrow, blood or LPH
samples from AML patients. (D) Plot depicts the frequency of
human myeloid cells (CD33+) within all engrafted human
leukocytes (hCD45+) according to the sample source.
(PDF)
Figure S2 Lack of correlation between the type of engraftment
and the cellular composition of the graft. Frequencies of hCD45+
CD3+ (A) or hCD45+ CD33+ (B, C) positive cells in the bone
marrow of NSG mice that were transplanted with 56106–107
freshly isolated MNCs from 13 (A) or 11 (B+C) AML patients
before. Frequency of CD3+ donor cells is depicted as a function of
CD3+ cells in the graft (A). Frequency of CD33+ donor cells is
depicted as a function of the number of AML blasts in the graft
(side scatterlow CD45+, B) or total leukocytes of the patient (C).
(PDF)
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Figure S3 Xenogeneic graft versus host disease leads to growth
retardation, splenomegaly and bone marrow hypoplasia. (A)
Picture shows NSG recipient mice that were transplanted 107
MNCs (PB) from a healthy donor 6 weeks before (Tx) and non-
transplanted control mice (ctrl.). Human donor-cell chimerism in
the peripheral blood, bone marrow and spleen was 32%, 19% and
86%, respectively, and in all organs.98% of all human leukocytes
expressed the CD3 antigen. Picture is representative for 5
independent recipient mice. (B) Femuras and tibias of mice that
had received MNCs from healthy individuals as described in (A)
were pale compared to control NSG mouse bones. (C) The spleen
of mice that had received MNCs from healthy individuals was
enlarged compared to a control spleen from a non-injected NSG
mouse. Spleens depicted originate from mice described in (A). (D)
Plot shows reduced bone marrow cellularity in mice that were
transplanted with 56106–107 MNCs from patients (left) or healthy
donors (right). Bone marrow hypoplasia is detected in mice
transplanted with MNCs from healthy individuals (1.861.46107)
and from AML patients (2.862.06107), compared to non-
transplanted NSG mice (middle, 4.361.86107). (E) Mean spleen
cellularity of mice transplanted with MNCs of healthy donors
(right, 4.669.16107) or AML patients (left, 4.968.46107) or
untreated NSG mice (middle, 0.762.76107). Mice received grafts
described in (D).
(PDF)
Figure S4 Transplantation of MNCs from healthy donors results
in almost exclusive engraftment of human T lymphocytes.
Unconditioned NSG mice were transplanted with 56106–107
MNCs freshly isolated from the bone marrow and blood of healthy
volunteers and leukapheresis products from G-CSF treated
donors. Mice were sacrificed 12 weeks after transplantation or
when status of health detoriated. (A) Mice transplanted with
MNCs from healthy donors showed a significant shortened
survival compared to mice transplanted with AML-MNCs. (B)
Transplantation of MNCs of healthy donors led to organ specific
chimerism that was determined at the time point of analysis. (C)
Donor-derived leukocytes in the blood, BM and spleen of NSG
mice that had received MNCs from healthy donors expressed
predominantly CD3+ T lymphocytes, while CD19+ B-lymphocytes
and CD33+ myeloid cells were barely detectable. (D) Plot shows
the frequency of TCRa/b+ and TCRc/d+ T cells in CD3+ cells,
and the frequency of the expression of CD4 and CD8 or both on
TCRa/b+ T cells on donor-derived lymphocytes in the bone
marrow of NSG recipient mice after the transplantation of MNCs
from healthy donors. (CD4:52.2615.7%, CD8:34.9614.1%,
CD4/CD8:10.565.5%, TCRa/b: 97.369.5% and TCRc/d:
0.0960.2%) (E) Plot shows the frequency of indicated Vb
segments in human a/b T cell receptors on T cells in the bone
marrow of NSG mice that had received MNCs from healthy
volunteers. Frequencies based on human CD45+ CD3+ cells are
shown. (F) Bar graph shows the frequency of human T
lymphocytes (hCD45+CD3+) that express CD25 and/or CD69
in blood, bone marrow and spleen of NSG recipient mice that
were transplanted with MNCs from healthy patients. N= 26 for all
groups.
(PDF)
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